DAG1 and prostate carcinoma: In a study examining the role of dystroglycan in prostate cancer cell lines, β-dystroglycan was shown to exhibit reversible cell density dependent changes in form, with lower molecular weight forms of 38–43 kDa due to mis-glycosylation and bands at 31 and 26 kDa resulting from proteolysis being seen in supra-confluent cells (52).